Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361724 | 0.77 | ALDH1A1 (0.36) | MAPTALDH1A1ATMMCL1 | |
| SCHEMBL9968964 | 0.77 | ALDH1A1 (0.36) | MAPTALDH1A1ATMMCL1 | |
| SCHEMBL14361721 | 0.77 | ALDH1A1 (0.36) | MAPTALDH1A1ATMMCL1 | |
| SCHEMBL2379059 | 0.76 | — | — | |
| SCHEMBL17617312 | 0.68 | ALDH1A1 (0.36) | MAPTALDH1A1ATMMCL1 | |
| SCHEMBL908521 | 0.67 | — | — | |
| SCHEMBL14751823 | 0.64 | — | — | |
| SCHEMBL18995445 | 0.63 | — | — | |
| SCHEMBL5181814 | 0.62 | — | — | |
| SCHEMBL2387695 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | CENTROSE LLC (US) | 2017-02-23 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-8703723-B2 | Glycoside compounds and pharmaceutical compositions thereof | CENTROSE, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130178431-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | CENTROSE, LLC (US) | 2013-07-11 | — | — | US | disclosed |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275683-A1 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | MAPT 129/4885ALDH1A1 415/4885ATM 2637/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | MAPT 4552/4885ALDH1A1 2970/4885ATM 4025/4885 |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | MAPT 226/4885ALDH1A1 3826/4885ATM 3713/4885 |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | PAICS, MAP2K4, GIPR | MAPT 4601/4885ALDH1A1 4138/4885ATM 4860/4885 |
| US-20170049908-A1 | EXTRACELLULAR TARGETED DRUG CONJUGATES | ENTPD1, ENTPD2, ENTPD3 | MAPT 2700/4885ALDH1A1 1286/4885ATM 3668/4885 |
| US-20120149743-A9 | Selenophene and Selenazole Carboxylic Acid Derivatives | DAO, DDO, SELENOI | MAPT 129/4885ALDH1A1 415/4885ATM 2637/4885 |
| US-20130178431-A1 | GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | UGCG, NFATC1, GAA | MAPT 3783/4885ALDH1A1 1948/4885ATM 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.